Diabetes phase II study shows positive results

Monday, March 14, 2011 01:50 PM

Amylin Pharmaceuticals, Eli Lilly and Alkermes announced positive results from a phase II study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type II diabetes.

This phase II, randomized, open-label study included 121 adults with type II diabetes who were not achieving adequate glucose control using diet and exercise alone or with a stable regimen of metformin, Actos (pioglitazone) or both. 

This phase II study assessed the efficacy, safety and tolerability of three different doses of exenatide once monthly. It also assessed exenatide once weekly (exenatide extended-release for injectable suspension, proposed brand name Bydureon), another investigational type II diabetes therapy. After 20 weeks of treatment (five injections), patients randomized to the exenatide once monthly treatment arms experienced average reductions in A1C ranging between 1.3% and 1.5% from baseline. In the once-weekly Bydureon treatment arm, the reduction was 1.5% points. A1C is a measure of average blood sugar over three months.

More than 90% of patients overall completed the study. The most common adverse events among the exenatide once monthly treatment groups were headache and nausea. Headache and diarrhea were most common among the once-weekly Bydureon group. No major or minor hypoglycemia was reported in the study.

This phase II, randomized, open-label study included 121 adults with type II diabetes who were not achieving adequate glucose control using diet and exercise alone or with a stable regimen of metformin, Actos (pioglitazone) or both. 

This phase II study assessed the efficacy, safety and tolerability of three different doses of exenatide once monthly. It also assessed exenatide once weekly (exenatide extended-release for injectable suspension, proposed brand name Bydureon), another investigational type II diabetes therapy. After 20 weeks of treatment (five injections), patients randomized to the exenatide once monthly treatment arms experienced average reductions in A1C ranging between 1.3% and 1.5% from baseline. In the once-weekly Bydureon treatment arm, the reduction was 1.5% points. A1C is a measure of average blood sugar over three months.

More than 90% of patients overall completed the study. The most common adverse events among the exenatide once monthly treatment groups were headache and nausea. Headache and diarrhea were most common among the once-weekly Bydureon group. No major or minor hypoglycemia was reported in the study.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 21

As job growth in drug development sector soars, more employees are seeking new opportunities

U.K. study: Prisoners should have the right to participatein clinical trials on moral grounds, for healthcare access

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs